1.Saijo N. Chemotherapy：the more the better？Cancer Chemother Pharmacol，1997，40（Suppl）：S100-106.

2.Porrata LF，Adjei AA. The pharmacologic basis of high dose chemotherapy with haematopoietic stem cell support for solid tumours. Br J Cancer，2001，85：484-489.

3.Demirer T，Buckner CD，Appelbaum FR，et al. Busulfan，cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia：phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant，1996，17：491-495.

4.Buser AS，Stern M，Bucher C，et al. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas：a comparison of delayed versus immediate transplantation. Bone Marrow Transplant，2007，39：335-340.

5.Lichtman SM，Etcubanas E，Budman DR，et al. The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment：a prospective dose adjustment study. Cancer Invest，2002，20：904-913.

6.Morgan RJ Jr.，Doroshow JH，Venkataraman K，et al. High-dose infusional doxorubicin and cyclo-phosphamide：a feasibility study of tandem high-dose chemotherapy cycles without stem cell support. Clin Cancer Res，1997，3：2337-2345.